170841 ⎘
Detection or diagnosis of diseases; Neurological disorders Dementia; Cognitive disorders
Sub-classes:METHODS FOR DIAGNOSING ALZHEIMER'S DISEASE AND OTHER NEUROLOGICAL DISORDERS
#2METHODS FOR REMOTE BLOOD COLLECTION, EXTRACTION AND ANALYSIS OF NEURO BIOMARKERS
#3Bcl2 Family in Dysfunctional Neurons Is Critical to the Evolution, Diagnosis and Treatment of Neurodegenerative Diseases Including but Not Limited to Corticobasal Degeneration, Chronic Traumatic Encephalopathy, Amyotrophic Lateral Sclerosis (Als), Alzheimer's Disease, Parkinson's Disease, Down's Syndrome Dementia, and Lewy Body Dementia
#4METHODS FOR TREATING AND MONITORING PROGRANULIN-ASSOCIATED DISORDERS
#5METHOD FOR MEASURING CELL FREE CHROMATIN
#6METHODS AND COMPOSITIONS FOR TREATING METABOLIC IMBALANCE IN NEURODEGENERATIVE DISEASE
#7COMP PEPTIDE AND ANTIBODIES THERETO FOR DIAGNOSING OSTEOARTHRITIS
#8METHODS OF DETERMINING CERULOPLASMIN ACTIVITY AND APPLICATIONS THEREOF
#9BLOOD-BASED SCREENING OF SUBJECTS FOR A CLINICAL TRIAL FOR TREATMENT OF TAUOPATHY OR AMYLOIDOGENIC DISEASE
#10PHOSPHO-TAU AGGREGATION-BASED BIOMARKERS FOR ALZHEIMER'S DISEASE DIAGNOSIS, DIFFERENTIATION, AND TREATMENT
#11DIAGNOSTIC METHOD
#12TEST METHOD FOR PHYSICAL FRAILTY, TEST REAGENT FOR PHYSICAL FRAILTY, METHOD FOR SCREENING THERAPEUTIC CANDIDATE SUBSTANCE FOR PHYSICAL FRAILTY, TEST MELTHOD FOR MENTAL FRAILTY, TEST REAGENT FOR MENTAL FRAILTY, AND METHOD FOR SCREENING THERAPEUTIC CNADIDATE SUBSTANCE FOR MENTAL FRAILTY
#13METHODS AND SYSTEMS FOR IDENTIFYING OR TREATING CENTRAL NERVOUS SYSTEMS DISEASE
#14METHOD AND COMPOSITION FOR GENERATING BASAL FOREBRAIN CHOLINERGIC NEURONS (BFCNS)
#15ANTIBODIES SPECIFIC FOR HYPERPHOSPHORYLATED TAU AND METHODS OF USE THEREOF
#16METHODS AND KITS FOR ASSESSING ALZHEIMER'S DISEASE
#17APPARATUS AND METHOD FOR IDENTIFYING COLLATERAL PROCESSES
#18p53 FRAGMENTS AS MARKERS FOR DIAGNOSIS AND PROGNOSIS OF NEURODEGENERATIVE DISEASE STATES
#19COMBINATION OF BIOMARKERS, AND METHOD FOR DETECTING COGNITIVE DYSFUNCTION OR RISK THEREOF BY USING SAID COMBINATION
#20METHOD FOR QUANTIFYING ACTIVE OREXIN A
#21DEVICE FOR DETECTION AND PROGNOSTIC ASSESSMENT OF NEURODEGENERATIVE DISORDERS
#22METHODS AND COMPOSITIONS FOR TREATING MICROGLIAL DYSFUNCTION AND IMPROVING METABOLIC DYSFUNCTION
#23METHOD OF ASSESSING RISK OF PML
#24Methods and Compositions for Evaluating Biomarkers in Salivary Exosomes and Evaluating Cognitive Fatigue
#25AMYLOID BETA DETECTION BY MASS SPECTROMETRY
#26METHODS FOR ASSESSING LIKELIHOOD OF POST-OPERATIVE DELIRIUM IN PATIENTS UNDERGOING SURGERY
#27ANTIBODY BASED REAGENTS THAT SPECIFICALLY RECOGNIZE TOXIC OLIGOMERIC FORMS OF TAU
#28ALPHA-SYNUCLEIN DETECTION ASSAY
#29ANIMAL, FUNGAL AND MARINE SOURCES OF CGP AND INCREASED CGP CONCENTRATION FOR DISEASE MANAGEMENT AND FOR TREATMENT OF NON-NEUROLOGICAL AND/OR NEUROLOGICAL CONDITIONS
#30USE OF ADNF POLYPEPTIDES IN THERAPY
#31ALPHA-SYNUCLEIN DETECTION ASSAY AND METHOD FOR DIAGNOSING ALPHA-SYNUCLEINOPATHIES
#32PERSONALIZED MEDICINE APPROACH FOR TREATING COGNITIVE LOSS
#33METHODS OF DIAGNOSING A SYNUCLEINOPATHY
#34SELECTION AND TREATMENT OF SUBJECTS HAVING A CIRCULATING MYELOID CELL INFLAMMATORY PHENOTYPE
#35METHODS FOR MEASURING UBIQUITIN CARBOXY-TERMINAL HYDROLASE L1 LEVELS IN BLOOD
#36Methods of Modifying Neuronal Function by Changing Intracellular Magnesium Levels
#37METHOD FOR THE EARLY DIAGNOSIS OF NEURODEGENERATIVE DISEASES BY MEANS OF QUANTIFICATION OF PRONGF AND DERIVED FORMS THEREOF
#38METHODS AND COMPOSITIONS FOR MONITORING PHAGOCYTIC ACTIVITY
#39IMMOBILIZED PROTEIN SYSTEM FOR RAPID AND ENHANCED MULTIPLEXED DIAGNOSTICS
#40HUMAN-DERIVED ANTI-DIPEPTIDE REPEATS (DPRS) ANTIBODY
#41ALPHA-SYNUCLEIN DETECTION USING BEADS
#42Precision Medicine Approach to Targeting Neurodegeneration
#43METHODS OF USE OF ANTI-SORTILIN ANTIBODIES
#44Levels of CSF-Seeded alpha-Synuclein Oligomers reflect Parkinson's Disease Severity
#45ALPHA-SYNUCLEIN SEED AMPLIFICATION ASSAY FOR PERIPHERAL MATRICES
#46JUDGMENT SUPPORTING INFORMATION GENERATING METHOD, JUDGMENT SUPPORTING INFORMATION GENERATING SYSTEM, AND INFORMATION PROCESSING DEVICE
#47METHODS FOR TREATING AND MONITORING FRONTOTEMPORAL DEMENTIA
#48IDENTIFYING RISK OF AND TREATING STROKE-INDUCED COGNITIVE IMPAIRMENT FOLLOWING THROMBECTOMY
#49SCG2 NEUROPEPTIDES AND USES THEREOF
#50Methods and Systems for Determining Autism Spectrum Disorder Risk
#51BIOMARKERS FOR COGNITIVE DYSFUNCTION DISEASES AND METHOD FOR DETECTING COGNITIVE DYSFUNCTION DISEASE USING BIOMARKERS
#52COMPOSITION FOR DIAGNOSING, PREVENTING, OR TREATING COGNITIVE DYSFUNCTION COMPRISING COTL1 AS ACTIVE INGREDIENT
#53DETERMINATION AGENT AND DETERMINATION METHOD FOR TAUOPATHY AND DEMENTIA-RELATED DISEASES
#54KINASES AS BIOMARKERS FOR NEURODEGENERATIVE CONDITIONS
#55CHEMILUMINESCENT PROBES
#56METHOD FOR DIAGNOSING AND TREATING COGNITIVE IMPAIRMENT AND USE THEREOF
#57BLOOD-BASED SCREEN FOR DETECTING NEUROLOGICAL DISEASES IN PRIMARY CARE SETTINGS
#58Compositions and Methods for Degradation of Misfolded Proteins
#59MULTIMARKER PANEL FOR THE ASSESSMENT OF SILENT BRAIN INFARCTS AND COGNITIVE DECLINE
#60IMMOBILIZED PROTEIN SYSTEM FOR RAPID AND ENHANCED MULTIPLEXED DIAGNOSTICS
#61TDP-43 BIOSENSOR CELL LINES
#62Methods of Modifying Neuronal Function by Changing Intracellular Magnesium Levels
#63METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION
#64Cell Lines Secreting Alpha-Synuclein Targeting Antibodies, Progranulin and Prosaposin and a Complex of Both, and GDNF
#65Methods For Detecting Phosphorylated Alpha-Synuclein
#66ADRENOMEDULLIN (ADM) FOR DIAGNOSIS AND/OR PREDICTION OF DEMENTIA AND ANTI-ANDRENOMEDULLIN BINDER FOR USE IN THERAPY OR PREVENTION OF DEMENTIA
#67BIOMARKER FOR DIAGNOSIS OF DEMENTIA
#68NON-HUMAN MAMMAL MODEL OF HUMAN DEGENERATIVE DISORDER, USES THEREOF, AND METHOD OF TREATING HUMAN DEGENERATIVE DISORDER
#69PATHOLOGIC TDP-43 AS A BIOMARKER FOR THE DIAGNOSIS OF TDP-43 PROTEINOPATHY
#70Methods and compositions for screening and treating developmental disorders
#71METHODS AND KITS FOR DIAGNOSING MILD COGNITIVE IMPAIRMENT
#72Methods of Modifying Neuronal Function by Changing Intracellular Magnesium Levels
#73TAU PROTEIN DETECTION METHOD USING BLOOD SAMPLE AS TEST SPECIMEN
#74Amyloid beta detection by mass spectrometry
#75Methods and compositions for monitoring phagocytic activity
#76Assay to detect and quantitate specific antibodies for various redox forms of HMGB1
#77Anti-TDP-43 Binding Molecules and Uses Thereof
#78Assay for the detection of alpha-synuclein seeding activity associated with synucleinopathies
#79METHOD FOR DETERMINING ALZHEIMER-TYPE DEMENTIA OR MILD COGNITIVE IMPAIRMENT
#80DIAGNOSTIC TEST FOR IDIOPATHIC NORMAL PRESSURE HYDROCEPHALUS
#81METHODS AND COMPOSITIONS FOR TREATING METABOLIC IMBALANCE IN NEURODEGENERATIVE DISEASE
#82CELL-FREE MIRNA BIOMARKERS FOR PROGNOSIS AND DIAGNOSIS OF NEURODEGENERATIVE DISEASES
#83ALPHA-SYNUCLEIN ASSAYS
#84Examination method for dementia or risk thereof
#85USE OF A PS396 ASSAY TO DIAGNOSE TAUOPHATIES
#86METHODS FOR DIAGNOSING ALZHEIMER'S DISEASE AND OTHER NEUROLOGICAL DISORDERS
#87Antibodies specific for hyperphosphorylated tau and methods of use thereof
#88Method for diagnosis of Alzheimer's disease using microrna
#89METHODS AND SYSTEMS FOR IDENTIFYING MODULATORS OF PERVASIVE DEVELOPMENTAL DISORDERS
#90TREATMENT OF SYNUCLEINOPATHY AND ANIMAL MODELS OF SYNUCLEINOPATHY
#91Methods for measuring ubiquitin carboxy—terminal hydrolase L1 levels in blood
#92MULTIPLEXED ASSAY AND METHODS OF USE THEREOF
#93NOVEL BIOMARKER FOR ALZHEIMER'S DISEASE IN HUMAN
#94Application of BAZ2B Gene as Target in Slowing Aging
#95METHODS FOR THE IDENTIFICATION, ASSESSMENT, PREVENTION, AND TREATMENT OF NEUROLOGICAL DISORDERS AND DISEASES
#96DIAGNOSING AND TREATING ALZHEIMERS DISEASE
#97METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
#98Method of assessing risk of PML
#99Alpha-synuclein detection assay and method for diagnosing alpha- synucleinopathies
#100COMPOSITION FOR DIAGNOSING MILD COGNITIVE IMPAIRMENT CONTAINING TonEBP ANTIBODY AS AN EFFECTIVE COMPONENT
#101SYSTEMS AND METHODS FOR IDENTIFYING AND TREATING NEURODEGENERATIVE DISEASE
#102METHODS FOR TREATING AND MONITORING PROGRANULIN-ASSOCIATED DISORDERS
#103Antibody based reagents that specifically recognize neurodegenerative disease related forms of the protein TDP-43
#104ANTI-SYNUCLEIN ANTIBODIES
#105Personalized Medicine Approach for Treating Cognitive Loss
#106Antibody based reagents that specifically recognize toxic oligomeric forms of tau
#107HISTONE ACETYLTRANSFERASE ACTIVATORS AND USES THEREOF
#108Alpha-synuclein detection using beads
#109ADRENOMEDULLIN (ADM) FOR DIAGNOSIS AND/OR PREDICTION OF DEMENTIA AND ANTI-ADRENOMEDULLIN BINDER FOR USE IN THERAPY OR PREVENTION OF DEMENTIA
#110EVALUATING METHOD, CALCULATING METHOD, EVALUATING APPARATUS, CALCULATING APPARATUS, EVALUATING PROGRAM, CALCULATING PROGRAM, RECORDING MEDIUM, EVALUATING SYSTEM, AND TERMINAL APPARATUS FOR MILD COGNITIVE IMPAIRMENT
#111METHOD FOR DIAGNOSING DEMENTIA OR DETERMINING THE RISK OF DEVELOPING DEMENTIA
#112Alpha-synuclein detection assay and method for diagnosing alpha-synucleinopathies
#113Parallel Enzyme Digestion for Protein Biomarker Detection
#114Compounds useful as near-infrared fluorescent probes selectively binding to tau aggregates and method of preparing the same
#115METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION
#116METHOD FOR DETECTION AND ANALYSIS OF CEREBROSPINAL FLUID ASSOCIATED UBE3A
#117DENDRITIC CELL RECRUITMENT FROM BLOOD TO BRAIN IN NEURODEGENERATIVE DISEASE
#118COMPOSITIONS AND METHODS FOR DETECTION AND IMAGING OF AMYLOID FIBRILS, AMYLOID PLAQUES, RNA, AND NUCLEOLI
#119Methods For Detecting Phosphorylated Alpha-Synuclein
#120DISEASE RISK ASSESSMENT APPARATUS, DISEASE RISK ASSESSMENT METHOD, COMPUTER READABLE MEDIUM, AND FOOD FOR DEMENTIA PREVENTION
#121Methods of binding amyloid beta protein having pyroglutamate at the third amino acid residue (3pE abeta) in vivo using anti-3pE abeta antibodies or antigen-binding fragments thereof
#122METHOD AND COMPOSITION FOR GENERATING BASAL FOREBRAIN CHOLINERGIC NEURONS (BFCNs)
#123Anti-Tau antibodies and methods of use
#124Disease detection method
#125METHOD AND APPARATUS FOR PREDICTING POSTTRAUMATIC BEHAVIOR PROBLEM
#126Alpha-synuclein detection using beads
#127METHODS OF DETECTING NEURODEGENERATIVE DISEASE
#128DETECTION OF ALZHEIMER'S DISEASE (AD), FRONTOTEMPORAL LOBAR DEGENERATION (FTLD), AMYOTROPHIC LATERAL SCHLEROSIS (ALS), PARKINSON'S DISEASE (PD), AND DEMENTIA WITH LEWY BODIES (DLB) INDICATED BY PHOSPHORYLATION OF MARCKS
#129Method for diagnosis of Alzheimer's disease using microRNA
#130METHODS OF ASSESSING FUTURE MEMORY LOSS BY MEASURING POLYUNSATURATED FATTY ACIDS
#131Diagnosing and treating Alzheimer's disease
#132BIOMARKERS FOR COGNITIVE DYSFUNCTION DISEASES AND METHOD FOR DETECTING COGNITIVE DYSFUNCTION DISEASE USING BIOMARKERS
#133Antibody based reagents that specifically recognize toxic oligomeric forms of tau
#134Methods of modifying neuronal function by changing intracellular magnesium levels
#135BIOMARKER
#136HUMAN ANTI-TAU ANTIBODIES
#137Assay for the detection of alpha-synuclein seeding activity associated with synucleinopathies
#138Use of acamprosate to modulate ERK1/2 activation in animal models for FXS and ASD and individuals diagnosed with FXS and ASD
#139IN VITRO METHOD FOR THE DETERMINATION OF NEURODEGENERATIVE DISEASES
#140Method for the diagnosis and prognosis of neurodegenerative and neuroinflammatory pathologies
#141Brain derived PPARα ligands
#142Biomarkers for cognitive impairment and methods for detecting cognitive impairment using such biomarkers
#143DEVICE AND METHOD FOR DIAGNOSIS OF ALZHEIMER'S SYMPTOMS
#144Methods of detecting pyroglutamate amyloid beta protein (3pE Aβ) using anti-3pE Aβ antibodies
#145Label-Free Single and Multi-Photon Fluorescence Spectroscopy to Detect Brain Disorders and Diseases: Alzheimer, Parkinson, and Autism From Brain Tissue, Cells, Spinal Fluid, and Body Fluids
#146DIAGNOSTIC MARKERS OF COGNITIVE IMPAIRMENTS, KITS AND USES THEREOF
#147METHODS OF MEASURING UBIQUITIN-LIKE MODIFICATIONS
#148BIOMARKER FOR ALZHEIMER'S DISEASE
#149COMBINATORIAL SYNTHESIS AND BIOMARKER DEVELOPMENT
#150Histone acetyltransferase activators and uses thereof
#151Antibodies specific for hyperphosphorylated tau and methods of use thereof
#152AFFINITY CAPTURE OF CIRCULATING BIOMARKERS
#153RARE PHOSPHORYLATED HIGH MOLECULAR WEIGHT (HMW) TAU SPECIES THAT ARE INVOLVED IN NEURONAL UPTAKE AND PROPAGATION AND APPLICATIONS THEREOF
#154BRAIN OSTEOCALCIN RECEPTOR AND COGNITIVE DISORDERS
#155Biomarker for mental disorders including cognitive disorders, and method using said biomarker to detect mental disorders including cognitive disorders
#156Anti-Tau antibodies and methods of use
#157TDP-43 specific binding molecules
#158Structure-based peptide inhibitors that target the Tau VQIINK fibrillization segment
#159A CELL-BASED ASSAY AND KITS FOR ASSESSING SERUM ANTICHOLINERGIC ACTIVITY
#160Metabolic biomarkers for cognitive ability
#161Human-derived anti-dipeptide repeats (DPRs) antibody
#162Systems and methods for binding amyloid fibrils using fluorescent protein
#163Osteocalcin as a treatment for cognitive disorders
#164NEURONS AND COMPOSITIONS AND METHODS FOR PRODUCING THE SAME
#165Methods for ameliorating memory impairment in a memory disorder caused by neuronal cell death or Abeta aggregation using a peptide
#166BIOMARKERS OF BLOOD-BRAIN BARRIER DYSFUNCTION
#167Alpha-synuclein detection assay and method for diagnosing alpha-synucleinopathies
#168Reducing abnormal accumulation of TDP-43 in motor neurons in amyotrophic lateral sclerosis and/or frontotemporal dementia using a construct encoding cyclin F
#169Antibodies specific for hyperphosphorylated tau and methods of use thereof
#170Antibodies specific for hyperphosphorylated tau and methods of use thereof
#171EVALUATING METHOD FOR MILD COGNITIVE IMPAIRMENT OR ALZHEIMER'S DISEASE
#172Antibody based reagents that specifically recognize neurodegenerative disease related forms of the protein TDP-43
#173Method For Quantifying Plasmalogens Using PLA1 Processing
#174COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDER
#175Diagnostic devices and methods of use
#176Methods and compositions for tauopathy diagnosis and treatment
#177Methods of treating a multiple sclerosis patient with anti-VLA-4 therapy
#178Methods and compositions for screening and treating developmental disorders
#179Diagnosing and treating Alzheimer's disease
#180BIOMARKERS AND DIFFERENTIAL DIAGNOSIS OF ALZHEIMER'S DISEASE AND OTHER NEURODEGENERATIVE DISORDERS
#181METHOD AND APPARATUS FOR PREDICTING POSTTRAUMATIC BEHAVIOR PROBLEM
#182Combinatorial synthesis and biomarker development
#183IN VITRO METHOD FOR THE DETERMINATION OF NEURODEGENERATIVE DISEASES
#184GLYCOPEPTIDES AND USES THEREOF
#185Brain derived PPARα ligands
#186CDK12 inhibitors and their uses
#187Methods for measuring ubiquitin carboxy-terminal hydrolase L1 levels in blood
#188Method and composition for generating basal forebrain cholinergic neurons (BFCNS)
#189Blood-brain barrier permeable peptide compositions comprising a VAB domain of an anti-amyloid-beta camelid single-domain heavy-chain only antibody
#190Human anti-alpha-synuclein antibodies
#191SOLUBLE HIGH MOLECULAR WEIGHT (HMW) TAU SPECIES AND APPLICATIONS THEREOF
#192SYSTEM OF PREDICTING DEMENTIA AND OPERATING METHOD THEREOF
#193Diagnosis of a neurological disease
#194Assay to detect and quantitate specific an antibodies for various redox forms of HMGB1
#195Methods and compositions for treating metabolic imbalance in neurodegenerative disease
#196Protein biomarkers for memory loss
#197ASTROCYTE DIFFERENTIATION PROTOCOL
#198Role of citrullination in diagnosing diseases
#199ANTIBODY BASED REAGENTS THAT SPECIFICALLY RECOGNIZE TOXIC OLIGOMERIC FORMS OF TAU
#200Method for quantifying plasmalogens using PLA1 processing
#201METHOD FOR PREDICTING RISK OF COGNITIVE DETERIORATION
#202Method of detecting an APP Alzheimer's disease marker peptide in patients with Alzheimer's disease
#203METHOD OF DIAGNOSING DEMENTIA AND APPARATUS FOR PERFORMING THE SAME
#204COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDER
#205DIAGNOSTIC TOOLS FOR ALZHEIMER'S DISEASE
#206DNA molecules encoding antibodies to tau and methods of making thereof
#207Diagnosing and treating Alzheimers disease
#208Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor
#209AFFINITY CAPTURE OF CIRCULATING BIOMARKERS
#210Biomarkers and diagnostic methods for Alzheimer's disease and other neurodegenerative disorders
#211Methods of assessing future memory loss by measuring polyunsaturated fatty acids
#212Methods for the treatment of neurological disorders
#213METHOD FOR DIAGNOSING A NEURODEGENERATIVE DISEASE
#214TRIM11 for degradation of protein aggregates
#215Antibodies to pyroglutamate amyloid-β and uses thereof
#216Alpha-Synuclein Antibodies (7A11)
#217METHOD FOR IDENTIFYING PARKINSON DISEASE DEMENTIA FROM PARKINSON DISEASE
#218Diagnostic markers of cognitive impairments, kits and uses thereof
#219Transgenic mouse model for dementia
#220BIOMARKERS AND DIAGNOSTIC METHODS FOR ALZHEIMER'S DISEASE AND OTHER NEURODEGENERATIVE DISORDERS
#221DUAL-TASK PERFORMING ABILITY EVALUATION METHOD AND DUAL-TASK PERFORMING ABILITY EVALUATION SYSTEM
#222LABEL-FREE SINGLE AND MULTI-PHOTON FLUORESCENCE SPECTROSCOPY TO DETECT BRAIN DISORDERS AND DISEASE: ALZHEIMER, PARKINSON AND AUTISM FROM BRAIN TISSUE, CELLS, SPINAL FLUID AND BODY FLUIDS
#223PREDICTIVE VALUE OF COMBINED GENETIC ENZYMATIC AND LIPIDOMIC DATA IN DISEASE RISK FOR LEWY BODY DISEASE
#224METHODS FOR THE IDENTIFICATION, ASSESSMENT, PREVENTION, AND TREATMENT OF NEUROLOGICAL DISORDERS AND DISEASES
#225Detecting Dementia and Alzheimer's Disease Associated Biomarkers Stabilized on Solid Support Materials
#226BIOMARKER OF DEMENTIA WITH LEWY BODIES
#227Indole and indoline derivatives and methods of use thereof
#228Antibodies specific for hyperphosphorylated tau and methods of use
#229HUMAN ANTI-TAU ANTIBODIES
#230Drug efficacy test method for dementias utilizing astrocyte-derived exosomes
#231AUTISM-ASSOCIATED BIOMARKERS AND USES THEREOF
#232Compounds for use as imaging agents
#233NOVEL BIOMARKERS FOR COGNITIVE IMPAIRMENT AND METHODS FOR DETECTING COGNITIVE IMPAIRMENT USING SUCH BIOMARKERS
#234BIOMARKER FOR COGNITIVE DYSFUNCTION DISEASES, AND METHOD FOR DETECTION OF COGNITIVE DYSFUNCTION DISEASES USING THE BIOMARKER
#235BIOMARKER FOR COGNITIVE DYSFUNCTION DISEASES, AND METHOD FOR DETECTION OF COGNITIVE DYSFUNCTION DISEASES USING THE BIOMARKER
#236Methods of modifying neuronal function by changing intracellular magnesium levels
#237Biomarkers in nasal exhaled breath
#238Human-derived anti-dipeptide repeats (DPRs) antibody
#239MICRORNA-132/212 FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS
#240Presence of Phosphorylated Tau Protein in the Skin of Neurodegenerative Disease and SCIS, SCC, and BCC
#241BIOMARKERS AND METHODS RELATING TO ALZHEIMER'S DISEASE
#242Quantifying biomarkers for diagnosing and treating schizophrenia, bipolar disorder or major depression
#243Antibody based reagents that specifically recognize toxic oligomeric forms of tau
#244Antibodies to Alpha Synuclein
#245Methods for detecting phosphorylated alpha-synuclein
#246EXOSOME AND LIPID BIOMARKERS FOR MEMORY LOSS
#247USE OF LEUKOCYTES AND NOVEL BIOMARKERS IN THE DIAGNOSIS, CONFIRMATION, AND TREATMENT OF A NEUROLOGICAL DISORDER
#248Non-human mammal model of human degenerative disorder, uses thereof, and method of treating human degenerative disorder
#249Non-human mammal model of human degenerative disorder, uses thereof, and method of treating human degenerative disorder
#250Detection of HIV-1-associated neurocognitive disorders
#251TDP-43 specific binding molecules
#252Pharmaceutical composition for preventing or treating neurodegenerative diseases
#253GLUTAMINYL CYCLASE AS A DIAGNOSTIC/PROGNOSTIC INDICATOR FOR NEURODEGENERATIVE DISEASES
#254Immobilized protein system for rapid and enhanced multiplexed diagnostics
#255Diagnostic devices and methods of use
#256Amyloid beta detection by mass spectrometry
#257Metabolic and Genetic Biomarkers for Memory Loss
#258Use of known compounds as D-amino acid oxidase inhibitors
#259Traumatic Brain Injury and Neurodegenerative Biomarkers, Methods, and Systems
#260Antibody based reagents that specifically recognize neurodegenerative disease related forms of the protein TDP-43
#261Biomarkers and differential diagnosis of alzheimer's disease and other neurodegenerative disorders
#262Methods of treating a tauopathy
#263DIAGNOSIS OF A NEUROLOGICAL DISEASE
#264SOLUBLE HIGH MOLECULAR WEIGHT (HMW) TAU SPECIES AND APPLICATIONS THEREOF
#265Non-human mammal model of human degenerative disorder, uses thereof, and method of treating human degenerative disorder
#266Diagnosing and treating alzheimer's disease
#267Personalized medicine approach for treating cognitive loss
#268Monitoring immunotherapy of Lewy body disease from constipation symptoms
#269Use of acamprosate to modulate ERK1/2 activation in animal models for FXS and ASD and individuals diagnosed with FXS and ASD
#270Antibodies that specifically bind ataxia telangiectasia-mutated and RAD3-related kinase phosphorylated at position 1989 and their use
#271Detection and removal of misfolded proteins/peptides
#272Methods and compositions for the treatment of symptoms of Williams Syndrome
#273Methods for increasing DISC1 in a subject with schizophrenia or bipolar disorder by an antagonist inhibiting DISC1 binding to FBXW7
#274BIOMARKERS FOR COGNITIVE DYSFUNCTION DISEASES AND METHOD FOR DETECTING COGNITIVE DYSFUNCTION DISEASE USING BIOMARKERS
#275Glycosylated PACAP/VIP analogues with enhanced CNS penetration for treatment of neurodegenerative diseases
#276AFFINITY CAPTURE OF CIRCULATING BIOMARKERS
#277Blood-based screen for detecting neurological diseases in primary care settings
#278Diagnostic testing in dementia and methods related thereto
#279COMPOSITION, FORMULATIONS AND METHODS OF MAKING AND USING BOTANICALS AND NATURAL COMPOUNDS FOR THE PROMOTION OF HEALTHY BRAIN AGING
#280METHODS AND COMPOSITIONS RELATING TO NEURODEGENERATIVE DISEASES
#281METHODS FOR DIAGNOSING AND ASSESSING NEUROLOGICAL DISEASES
#282Method of In Vitro Diagnosis of a Neurological Disorder
#283Method for diagnosis of dementias and neuroinflammatory diseases based on an increased level of procalcitonin in cerebrospinal fluid
#284METHODS AND SYSTEMS FOR DETERMINING AUTISM SPECTRUM DISORDER RISK
#285METHOD FOR TESTING RISK OF MULTIPLE SYSTEM ATROPHY, TEST KIT, AND DRUG FOR THE TREATMENT OR PREVENTION OF MULTIPLE SYSTEM ATROPHY
#286Method for detecting aSyn-specific antibodies in a biological sample
#287Uses of antibodies directed against amyloid-β
#288Osteocalcin as a treatment for cognitive disorders
#289Methods and compositions for improving cognitive function
#290Methods and compositions for modulating Tau levels
#291Methods for evaluating brain-wide paravascular pathway for waste clearance function and methods for treating neurodegenerative disorders based thereon
#292Diagnosis of Alzheimer Disease, Cognitive Decline and Dementia
#293METHODS AND ASSAYS RELATING TO RNF216
#294AGENTS, KITS AND METHODS FOR COMPLEMENT FACTOR H-RELATED PROTEIN 1 DETECTION
#295Human anti-tau antibodies
#296BIOMARKERS FOR CHRONIC TRAUMATIC ENCEPHALOPATHY
#297TEST METHOD AND TEST KIT FOR PSYCHIATRIC AILMENTS
#298Methods and systems for determining autism spectrum disorder risk
#299Agonistic autoantibodies to the alpha1-adrenergic receptor and the beta2-adrenergic receptor in Alzheimer's and vascular dementia
#300Antibody based reagents that specifically recognize toxic oligomeric forms of tau